目标公司（即EPS Innovative Medicine（Hong Kong）Limited）为一家在中国香港注册成立的有限责任公司，主要业务为投资控股目标集团的其他成员公司 ...

目标公司(即EPS Innovative Medicine(Hong Kong)Limited)为一家在中国香港注册成立的有限责任公司，主要业务为投资控股目标集团的其他成员公司，以及持有一 ...

公司有条件同意出售而买方有条件同意收购目标公司EPS Innovative Medicine（Hong Kong）Limited的全部已发行股本，代价为1.00日圆。 根据买卖协议，公司亦 ...

Shares of Prime Medicine, Inc. (NYSE:PRME – Get Free Report) have earned a consensus rating of “Buy” from the ten brokerages ...

Bank of New York Mellon Corp boosted its holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 5.4% during the 4th quarter, according to its most recent disclosure with the ...

Reports FY24 revenue $2.983M vs $0 last year. “Entering 2025 marks the next chapter for Prime Medicine (PRME) as we look to share initial data for our most advanced product candidate ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on IRON: Disc Medicine NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Editas Medicine reported earnings per share of -76 cents. This was below the analyst estimate for EPS of -67 cents. The company reported revenue of $1.14 million. This was 85.63% worse than the ...